ITPRIPL1 and non-small cell lung carcinoma: Furthermore, the immunohistochemical positivity of ITPRIPL1 might be crucial for eligible patients receiving anti-ITPRIPL1 treatment, which is irreplaceable by other NSCLC biomarkers regarding this aspect.